Please login to the form below

Not currently logged in
Email:
Password:

Mark Booth joins Probiodrug

He becomes chief business officer

Probiodrug Mark BoothHalle, Germany-based Probiodrug has appointed Mark Booth as its chief business officer and member of its management board.

Booth joins the Alzheimer's disease specialty biopharmaceutical firm from Orexigen Therapeutics, where he served as chief commercial officer leading its business development and investor relations activities.

He brings over 30 years of biopharmaceutical experience to Probiodrug and has held key positions at Abbott Laboratories, Immunex Corporation and Takeda Pharmaceuticals, where he served as president of its North America operations.

Dr Erich Platzer, chairman of Probiodrug's supervisory board, said: “Mark's broad business background and proven track record make him a valuable addition to our management board.

“His extensive experience in business development and investor relations will be instrumental to propel Probiodrug's strategy internationally and in particular [in] the United States.”

Booth said: “This is truly a unique opportunity and I look forward to working with the team as we advance new and novel therapeutic treatments for Alzheimer's patients.”

31st March 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...
Can you survive without the blue dot?
Or has the digital world has replaced our brain...
Alzheimers incidence
A roadmap to the successful treatment of Alzheimer’s disease
Building on past research to learn more about the disease and how to treat it...

Infographics